Storm Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Storm Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11097
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Storm Therapeutics Ltd (Storm Therapeutics) a spin-out of University of Cambridge is focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer and other diseases. The company is engaged in modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. It utilizes latest insights and emerging data from its collaborations build a unique target discovery platform for the identification of new drug targets. The company partners with the research groups using cutting-edge techniques such as chemical biology, RNA-Seq and RNA mass spectrometry to identify their protein writers, readers and erasers. Storm Therapeutics is headquartered in Cambridge, England, the UK.

Storm Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Storm Therapeutics Raises Additional USD5.4 Million in Series A Financing 10
Storm Therapeutics Raises USD16 Million in Series A Venture Financing 11
Storm Therapeutics Raises USD0.8 Million in Seed Financing 12
Partnerships 13
Evotec Expands Agreement with Storm Therapeutics 13
Licensing Agreements 14
Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 14
Equity Offering 15
Storm Therapeutics Spin Off from University of Cambridge 15
Storm Therapeutics Ltd – Key Competitors 16
Storm Therapeutics Ltd – Key Employees 17
Storm Therapeutics Ltd – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Nov 06, 2017: STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research 19
Feb 24, 2017: Storm Therapeutics announces Management Changes 20
Government and Public Interest 21
Nov 27, 2017: STORM Therapeutics Announces Publication in Nature on RNA Epigenetics by Founder Professor Tony Kouzarides 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Storm Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Storm Therapeutics Raises Additional USD5.4 Million in Series A Financing 10
Storm Therapeutics Raises USD16 Million in Series A Venture Financing 11
Storm Therapeutics Raises USD0.8 Million in Seed Financing 12
Evotec Expands Agreement with Storm Therapeutics 13
Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 14
Storm Therapeutics Spin Off from University of Cambridge 15
Storm Therapeutics Ltd, Key Competitors 16
Storm Therapeutics Ltd, Key Employees 17

List of Figures
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Storm Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Storm Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fanuc Corp (6954):企業の財務・戦略的SWOT分析
    Fanuc Corp (6954) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Technicolor SA:企業の戦略・SWOT・財務情報
    Technicolor SA - Strategy, SWOT and Corporate Finance Report Summary Technicolor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • GVK Power and Infrastructure Ltd (GVKPIL):企業の財務・戦略的SWOT分析
    GVK Power and Infrastructure Ltd (GVKPIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Arkema SA:企業の戦略・SWOT・財務分析
    Arkema SA - Strategy, SWOT and Corporate Finance Report Summary Arkema SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Stanwell Corporation Ltd:企業の戦略的SWOT分析
    Stanwell Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Gamma Medica Inc:医療機器:M&Aディール及び事業提携情報
    Summary Gamma Medica Inc (Gamma Medica), formerly Gamma Medica Ideas Inc is a medical device company that offers imaging solutions. The company designs, develops and manufactures imaging systems for clinical and pre-clinical applications. It offers lumagem, lumagem mbi workflow, lumagem procedure ov …
  • PhaseBio Pharmaceuticals Inc:企業のM&A・事業提携・投資動向
    PhaseBio Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PhaseBio Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Medifast Inc (MED):企業の財務・戦略的SWOT分析
    Medifast Inc (MED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mateon Therapeutics Inc (MATN):企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • PEPKOR RETAIL LIMITED:企業の戦略・SWOT・財務分析
    PEPKOR RETAIL LIMITED - Strategy, SWOT and Corporate Finance Report Summary PEPKOR RETAIL LIMITED - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tesco Corporation:石油・ガス:M&Aディール及び事業提携情報
    Summary Tesco Corp (Tesco), a subsidiary of Nabors Industries Ltd, is an oilfield technologies company. It sells and rents top drives and automated pipe handling equipment; and offers tubular services, including related products and accessories sales and aftermarket sales and services. The company o …
  • Centene Corp (CNC):企業の財務・戦略的SWOT分析
    Centene Corp (CNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Credit Guarantee Insurance Corporation of Africa Ltd:企業の戦略・SWOT・財務分析
    Credit Guarantee Insurance Corporation of Africa Ltd - Strategy, SWOT and Corporate Finance Report Summary Credit Guarantee Insurance Corporation of Africa Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's st …
  • DSG Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DSG Inc (DSG) is a provider of eClinical software solutions. The company offers software products such as eCaseLink EDC, eClinDirect CTMS, eCaseLink.Me ePRO, DSG Drug Safety, eCaseLink IRT, DSG Designer, CaseXport, CaseView Imaging, and others. Its services include data management, technolog …
  • Natera Inc (NTRA):医療機器:M&Aディール及び事業提携情報
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, g …
  • Trevena Inc (TRVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination w …
  • Southwest Gas Holdings Inc:企業の戦略・SWOT・財務情報
    Southwest Gas Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Southwest Gas Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Genting Singapore Plc:戦略・SWOT・企業財務分析
    Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report Summary Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Israel Electric Corporation Ltd-エネルギー分野:企業M&A・提携分析
    Summary The Israel Electric Corporation Ltd (IECL), formerly Palestine Electric Corporation Ltd. is an integrated electric utility that carries out the generation, transmission, distribution, sale and supply of electricity. The State of Israel owns around 99.85% of the company. It generates power ma …
  • NeuroMetrix Inc (NURO):医療機器:M&Aディール及び事業提携情報
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆